R. Sims

发表

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

P. Kantoff, P. Schellhammer, C. Redfern, 2010, The New England journal of medicine.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

S. Shen, R. Meredith, A. Lobuglio, 2005, Cancer biotherapy & radiopharmaceuticals.

G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb.

B. Calabretta, G. Anfossi, R. Sims, 1989, Science.

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

A. Pantuck, L. Klotz, D. George, 2011, The Journal of urology.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

J. Vose, M. Goris, S. Shen, 2004, Blood.

Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.

L. Esserman, John W. Park, M. Melisko, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

P. Carroll, C. Amling, E. Small, 2014, Journal of the National Cancer Institute.

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

D. Albala, M. Emberton, V. Mouraviev, 2014, Reviews in urology.

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

R. Sims, 2011, Journal of Cancer.

radioimmunotherapy for B-cell non-Hodgkin's lymphoma Phase I trial of a novel anti-CD20 fusion protein in pretargeted

J. Vose, S. Shen, A. Forero, 2013 .

Phase 1 trial of a novel anti-CD 20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

J. Vose, M. Goris, S. Shen, 2004 .

Magnetic resonance imaging characteristics of renal tumors after radiofrequency ablation.

J. Cadeddu, R. Sims, R. Svatek, 2006, Urology.

Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.

J. Friedberg, J. Goldschmidt, R. Sims, 2020 .

Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.

B. Calabretta, M. Ratajczak, A. Gewirtz, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

P. Kantoff, P. Schellhammer, G. Chodak, 2013, Urology.

An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer.

Johnathan C. Maher, J. Corman, R. Flanigan, 2013, The Journal of urology.

Human megakaryocytopoiesis.

A. Gewirtz, R. Sims, 1989, Annual review of medicine.

A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T

P. Kantoff, C. Higano, E. Small, 2014, Cancer Immunology Research.

Elevated Eosinophils Following Treatment with Sipuleucel-T In Men with Prostate Cancer Is Associated with Antigen-Specific Immune Response and Prolonged Survival.

J. Whitmore, R. Sims, M. Frohlich, 2010 .

Increased Gamma Globulin Following Immunotherapy with Sipuleucel-T Is Associated with Antigen-Specific Antibody Responses

M. Wener, R. Sims, N. Sheikh, 2010 .

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

R. Sims, 2012, Vaccine.

Combining immunotherapy and radiation for prostate cancer.

T. Devries, N. Shore, R. Sims, 2015, Clinical genitourinary cancer.

A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

S. Alberts, John W. Park, M. Melisko, 2009, Clinical Cancer Research.

Clinical Trials and Emerging Therapeutic Strategies in Bladder Cancer

J. Rosenberg, R. Bambury, R. Sims, 2015 .

TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)

C. Sternberg, T. Lebret, A. Merseburger, 2016 .

Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

P. Sharma, D. Bajorin, S. Lerner, 2013 .

HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.

E. Plimack, P. Sharma, D. Bajorin, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).

M. Cooperberg, A. Armstrong, C. Higano, 2014, Clinical advances in hematology & oncology : H&O.

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

T. Larson, J. Friedberg, J. Goldschmidt, 2020 .

BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)

N. Bartlett, R. Sims, W. Harwin, 2021, Hematological Oncology.

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).

N. Bartlett, R. Sims, G. Nowakowski, 2021 .

Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

N. Bartlett, R. Sims, G. Nowakowski, 2020 .

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

R. Sims, 2011, Journal of Cancer.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

P. Kantoff, P. Schellhammer, C. Redfern, 2010, The New England journal of medicine.

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

D. Albala, M. Emberton, V. Mouraviev, 2014, Reviews in urology.

Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment.

P. Carroll, V. Weinberg, C. Amling, 2012 .

Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

D. McNeel, D. Lin, R. Dreicer, 2012 .

Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial.

P. Kantoff, P. Schellhammer, G. Chodak, 2012 .